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Morphologic transition from the yeast to the
hyphal state in Candida albicans is associated
with pathogenicity of this human pathogen.
Such invasive transition of C. albicans cells is
regulated by numerous cell signal transduction
pathways, one of which involves a small
GTPase, the C. albicans Cdc42 (CaCdcd42),
with specific binding to downstream effectors,
e.g., CaCla4 and Cst20, containing CRIB do-
mains. Here, we report that in vivo inhibition of
CaCdc42 by peptide-mediated transduction
of the CRIB polypeptides can inactivate and
even reverse the pathogenically related mor-
phologic transition of C. albicans. The current
work provides a promising strategy for disease
intervention through disrupting protein-protein
interactions in signal transduction pathways
and brings the concept of signal transduction
therapy into the front line of antifungal design
as well as therapy for other signal transduction-
related diseases.
INTRODUCTION
Cellular signal transduction mediates the conversion of
external signals (hormones, growth factors, neurotrans-
mitters, and cytokines) to a specific internal cellular re-
sponse (gene expression, cell division, or even apoptosis),
and this transduction plays an important role in cell growth
and differentiation. The checks and balances of these sig-
nal transduction pathways can be thought of as overlap-
ping networks of interacting molecules that control ‘‘go–
no go’’ control points [1, 2]. As almost all known diseases
exhibit dysfunctional aspects in these networks, there
has been a great deal of enthusiasm for the prospect of
identifying novel drug targets based on knowledge of key
signal transduction components and their links to human
diseases [3–5]. Signal transduction pathways are typically
regulated by protein-protein interactions, which are medi-
ated by specific modular domains and form an important
mechanism for controlling signal transduction pathwaysChemistry & Biology 14, 1273–128[6]. Conversely, aberrant protein-protein interactions can
disturb cellular function and/or proliferation, contributing
to disease processes. Proteins encoded by pathogenic
bacteria and viruses, or chimeric cellular oncoproteins,
frequently exert their effects by disrupting normal protein-
protein interactions, and thus reorganizing cellular
behaviors [7, 8]. Recently our understanding of cellular sig-
nal transduction has been enhanced by rewiring signal
pathways through scaffold engineering [9] and synthetic
biology [10]. As such, one can use the prevalent interaction
domains to facilitate the formation of new connections
between existing signaling proteins, and thus to create
new signaling pathways during the course of cellular prolif-
eration [11].
Candida albicans is an opportunistic fungal pathogen
that is found in the gastrointestinal flora of most healthy
humans. This organism is the cause of most ‘‘yeast infec-
tions’’ in humans. C. albicans can proliferate to produce
blood-borne infections that often cause death in immuno-
compromised patients. C. albicans can exist in three
morphologic forms as yeast cells, pseudo hyphal cells,
and hyphal cells [12]. The pathogenicity of C. albicans is
contingent upon its ability to switch from yeast to hyphal
growth in response to environmental signals [13–16].
This transition is regulated by numerous cell signal trans-
duction pathways, one of which involves C. albicans
Cdc42 (CaCdcd42), a small GTPase of the Rho family,
with specific binding to downstream kinase effectors con-
taining CRIB (Cdc42/Rac interactive binding) domains
(e.g., CaCla4 and Cst20). CaCdc42 is required for polar-
ized growth of both the yeast and hyphal forms of C. albi-
cans [17], suggesting that CaCdc42 is probably related to
the establishment of a polarized actin cytoskeleton during
hyphal induction. As an essential gene, the deletion of
both CaCdc42 alleles can completely abolish the yeast-
to-hyphal transition of C. albicans cells. Furthermore, sig-
nal transduction from CaCdc42 to its two downstream
kinase effectors, Cst20 and CaCla4, is required for hyphal
growth under all experimental conditions examined [18,
19], through the interactions of Cdc42 with their CRIB
domains. Biochemical assays revealed that the extended
polypeptides (eCRIBs), containing the CRIB consensus
sequence and a short segment C-terminal to the CRIB do-
main, have high-affinity binding to CaCdc42 in apparent
low-nanomolar concentrations [20]. Significantly, these2, November 2007 ª2007 Elsevier Ltd All rights reserved 1273
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Inhibition of Morphologic Transition in Candidaresults suggest that CaCdc42 can be a potential target for
curbing candidiasis, and that Candida eCRIB peptides
can function as potent inhibitors of CaCdc42 in vivo. Ad-
ministration of such inhibitors can block CaCdc42 activity
and interrupt the yeast-to-hyphal transition. However, one
of the challenges is that C. albicans is a eukaryote, as are
other fungal pathogens, possessing biological machinery
similar to that of human cells. This similarity complicates
the development of more selective antifungal therapies.
Recently, many signal peptide sequences have been
thoroughly investigated to identify transducing molecules
enabling protein entry into bacteria and yeast [21, 22]. Of
particular interest for antifungal drug design is a peptide
with an amino acid sequence of VLTNENPFSDP, called
a NPF domain, which can trigger protein transduction
into bacteria and, more interestingly, into C. albicans
[23]. In the current work, we constructed NPF-eCRIB
fusion peptides as putative antifungal agents that can
interrupt CaCdc42-linked signal transduction pathways.
The delivery of Cdc42-specific eCRIB peptides via the
NPF domain into C. albicans cells should inactivate the
CaCdc42 protein, and subsequently inhibit the virulent
yeast-to-hyphal transition. Our results show that the
eCRIB domains derived from CaCla4 and Cst20 specifi-
cally inhibit hyphal growth of C. albicans cells in vivo
only after being conjugated to the cell-internalizing NPF
sequence. Therefore, our work provides a promising
approach to the design of new antifungal agents through
specific intervention of cell signal transduction.
RESULTS
Design of Specific eCRIB-Based Peptide Inhibitors
of CaCdc42
C. albicans eCRIB peptides cannot be directly used as
antifungal agents because of two challenging reasons.
First, C. albicans eCRIB domains are highly homologous
to their human counterparts, e.g., the eCRIB domain of
PAK-family kinases (Figure 1A); thus, theymay not be spe-
cific to CaCdc42. Second, the cell wall of C. albicansmay
limit peptide diffusion across the cell membrane. As such,
in an attempt to utilize Candida eCRIB peptides to design
specific inhibitors, it is necessary to examine whether C.
albicans eCRIB peptides can interact with human Cdc42
(HsCdc42). Binding assays of C. albicans eCRIB peptides
to HsCdc42 were determined by monitoring the change
of fluorescence signal intensity of sNBD, conjugated to
HsCdc42, as a function of peptide concentration. As
shown in Figure 1A, the two C. albicans eCRIBs exhibit
micromolar binding affinities for HsCdc42, although they
are much weaker than those for CaCdc42, indicating
that C. albicans eCRIB peptides are somewhat specific
to CaCdc42.
In this work, we would like to utilize NPF-mediated pro-
tein transduction to enhance the specificity of eCRIB pep-
tides to CaCdc42 rather than to optimize the selectivity of
eCRIB peptides, because the former strategy will localize
CaCdc42 binding to withinC. albicans cells. Asmentioned
previously, the NPF domain was proven to be functionally1274 Chemistry & Biology 14, 1273–1282, November 2007 ª20unique to bacteria and yeasts. Particularly, the NPF
domain has been extensively examined and shown to effi-
ciently transduce small-molecule compounds (e.g., FITC)
and proteins (e.g., Rectin A and Green fluorescent protein
[GFP]) into S. cerevisiae andC. albicans cells [22, 23]. Pre-
vious investigations also indicated that the NPF peptide-
mediated internalization into yeast cells was independent
of its position of incorporation in the host fusion protein
[23]. Therefore, in the current work, the NPF domain was
arbitrarily placed at the N terminus of designed fusion pro-
teins or peptides. Figure 1B lists two NPF-conjugated
eCRIB peptides, defined as NPF-eCaCla4 (I) and NPF-
eCst20 (II), respectively. These two NPF-eCRIB peptides
were prepared through a well-developed recombinant
peptide expression system (see Experimental Proce-
dures). The conjugated peptides were overexpressed
as fusion proteins in Escherichia coli BL21(DE3) cells
(Figure 1Ba). The peptides were released from the fusion
proteins by chemical cleavage via CNBr and purified by
HPLCwith a C18 reverse-phase chromatographic column.
The purity of the final products was determined to be
95%–99% by using a 20% SDS-PAGE gel (Figure 1Bb)
as well as an analytical HPLC assay (data not shown).
The identity of the purified peptides was confirmed by
electrospray mass spectrometry, as shown in Figure 1C
for the NFP-eCaCla4 peptide.
Importantly, the twoNPF-eCRIB peptides were found to
retain high-affinity binding to CaCdc42 comparable to the
eCRIBs alone (Figure 1B). These twoNPF-eCRIB peptides
also strongly inhibit the Cdc42-mediated activation of two
C. albicans kinases (i.e., Cst20 and CaCla4) in in vitro
assays (see Figure S1 in the Supplemental Data available
with this article online). However, the NPF domain itself
was confirmed to have no significant binding affinity to
CaCdc42.Moreover, the NPF-eCRIB peptideswere found
to exhibit similar conformational flexibility as those of the
CRIB peptides alone [20, 24], as indicted by the narrow
dispersion of their 1H-15N-NMR HSQC peaks (see
Figure 1D for NPF-eCaCla4 peptide).
Specificity of Putative Antifungal Peptides
to Candida Cells
C. albicans cells grow in the yeast form at 25C in Lee’s
medium or at 30C in YPD medium (Figures 2Aa and
2Ac). As shown in Figures 2Ab and 2Ad, the yeast cells
can readily be triggered to grow into the hyphal form by
simply increasing culture temperature and/or the addition
of serum (e.g., 37C in Lee’s medium or 37C in YPD
medium with 10% bovine serum). To examine whether
the NPF-eCRIB peptides could penetrate into C. albicans
cells, Lee’s mediumwas primarily used in the current work
because of simplicity.
Initially, the internalization of two NPF-eCRIB peptides
into mammalian cells and C. albicans cells was compared
by monitoring GFP fluorescence. The GFP protein was
fused to the C terminus of the NPF-eCRIB peptides, and
schematic representations of two GFP fusion proteins are
shown in Figure 2B. Apparently, one of theGFP-conjugated
NPF-eCRIB fusion proteins, i.e., NPF-eCaCla4-GFP,07 Elsevier Ltd All rights reserved
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Inhibition of Morphologic Transition in CandidaFigure 1. Design of Peptide-Mediated eCRIB Peptides as Putative Antifungal Agents
(A) The extended CRIB peptides (eCRIBs) of two C. albicans kinases, CaCla4 and Cst20, are highly homologous to that of human PAK1 kinase.
(B) The top shows two NPF-conjugated eCRIB peptides with high-affinity binding to CaCdc42. In (a), the expression of the fusion proteins containing
NPF-eCRIB peptides in LBA medium was evaluated by a 12% SDS-PAGE gel. Lane M, molecular weight marker; lanes 1 and 2, the fusion carrier
proteins; lane 3, NPF-eCaCla4 fusion proteins; and lanes 4–6, NPF-eCst20 fusion proteins. In (b), NPF-eCRIB peptides purified with HPLC were eval-
uated by a 20% SDS-PAGE gel. Lane M, molecular weight marker; lanes 1–3, NPF-eCaCla4 peptides; lanes 4–6, NPF-eCst20 peptides; and lane 7,
the fusion carrier protein.
(C) Mass spectrum of NPF-eCaCla4 with an ES-TOF spectrometer indicates a correct molecular weight close to its theoretical value (i.e., 6221.7 Da).
(D) 1H-15N HSQC spectrum of the NPF-eCst20 peptide.could not be internalized into HeLa cells, as shown in
Figures 2Ba and 2Bb. The GFP-conjugated NPF-eCst20
fusion protein, i.e., NPF-eCst20-GFP, exhibited the same
resistance to cellular uptake (see Figure S2). However,
when the GFP fusion proteins were incubated withC. albi-
cans cells composed of yeast and hyphal forms, the fusion
proteins exhibited specific targeting to hyphal cells. The
GFP fusion proteins not only penetrated into the hyphal
cells (Figures 2Ca and 2Cc), but also accumulated on
the surface of hyphal cells (see Figure 2Cc for NFP-
eCaCla4-GFP). Contrary to our expectations, both fusion
proteins had not been observed to penetrate into C. albi-
cans yeast cells under the current experimental conditions
(Figure 2C). GFP alone was unable to penetrate into C. al-
bicans cells under the same conditions (data not shown),
as reported previously [23].
Furthermore, the internalization of NPF-eCRIB peptides
into hyphal cells was confirmed by quantitating radiois-Chemistry & Biology 14, 1273–1282otope-labeled peptides in various cell fractions. As shown
in Figure S3, 43%–72% of NPF-eCRIB peptides are
mainly found in the cellular fraction composed of cell walls
and membranous proteins. Peptides could be trapped
in cell walls or be bound to Cdc42 because Cdc42 is a
membrane-bound protein. On the other hand, 16%–42%
of NPF-eCRIB peptides are identified from the cellular
fraction containing cellular cytoplasm of hyphal cells. Nev-
ertheless, each NPF-eCRIB peptide can maintain a high
peptide concentration in both cellular fractions up to at
least 25 hr.
Inhibition of Hyphal Growth by Putative
Antifungal Peptides
In order to evaluate whether NPF-eCRIB peptides have
antifungal activity againstC. albicans hyphal growth, a rel-
atively high concentration of peptides was arbitrarily
selected (i.e., 100 mM). Initially, the effect of the peptides, November 2007 ª2007 Elsevier Ltd All rights reserved 1275
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Inhibition of Morphologic Transition in CandidaFigure 2. NPF-eCRIB Peptides Preferentially Bind to Candida Hyphal Cells
(A) Dimorphism of C. albicans cells.
(B) The top shows schematic representations of two NPF-eCRIB-GFP fusion proteins. (a) and (b) show micrographs of HeLa cells after they were
incubated with NPF-eCla4-GFP protein.
(C) Micrographs of C. albicans cells after they were incubated with NPF-eCst20-GFP protein ([a] and [b]) or NPF-eCaCla4-GFP protein ([c]
and [d]).1276 Chemistry & Biology 14, 1273–1282, November 2007 ª2007 Elsevier Ltd All rights reserved
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Inhibition of Morphologic Transition in CandidaFigure 3. Inhibition of the C. albicans Yeast-to-Hyphal Transition by NPF-eCRIB Peptides
(A–L) Each peptide was added into fresh yeast-cell cultures at a final concentration of 100 mM. Different types of cells are shown in the insets.on the yeast-to-hyphal transition was examined. C. albi-
cans yeast cells grown overnight in Lee’s medium at
25C were transferred into fresh Lee’s medium and cul-
tured at 37C, and the cells began development of hyphae
within 3 hr (Figure 3A). If the NPF-eCaCla4 peptide was
added to the above-described fresh Lee’s medium (the
culture temperature was 37C), most of the cells still
remained in yeast form. Yeast cells were prone to aggre-
gation with increasing culture time (Figures 3E–3H). Al-
though some hyphal cells were observed in the cultures,
it seems that hyphal cells are fragmentized through cell
lysis (Figures 3E and 3F). In contrast, if NPF-eCst20 pep-
tide was added into the freshmedium and the culture tem-
perature was adjusted to 37C, no cell aggregation and
cell lysis were observed (Figures 3I–3L). Within 8 hr, C.
albicans cells remained in either yeast forms or pseudo
hyphal forms. The amount of yeast cells increased with
increasing culture time, implying that both of the peptides
can block the morphologic transition of C. albicans cells,
but not its yeast-cell proliferation. Taken together, both
the peptides dramatically reduced the amounts of hyphal
cells in culture, compared to cultures in the presence of
NPF-CRIB peptides (Figures 3A–3D). However, it was un-
clear whether yeast cells were reversed from hyphal form
or were simply maintained in the yeast-cell form in the
presence of peptides in medium.
In the next step, the same peptide concentration as that
in the aforementioned experiments was used to examine
whether the NPF-eCRIB peptides can inhibit hyphal
growth. C. albicans hyphal cells, which were prepared
from overnight cultures in Lee’s medium at 37C, wereChemistry & Biology 14, 1273–128inoculated into fresh Lee’s medium and continued to
grow in hyphal proliferation in the absence of peptides
(Figures 4A–4D). If the NPF-eCaCla4 peptide was added
into the fresh medium during hyphal growth, it appeared
that the hyphal cells were fragmented and switched to
yeast-like forms (Figures 4E–4H). The population of yeast
cells increased with increasing culture time, although
hyphal cells were observed (insets in Figure 4H). If NPF-
eCst20 peptide was added to the fresh medium during
hyphal growth, the numbers of yeast cells markedly in-
creased with time in culture, whereas the numbers of
hyphal cells dramatically decreased (Figures 4I–4L).
These observations suggested that hyphal cells can be
reversely transitioned into yeast forms. Conversely, in
control experiments in the absence of peptides, no yeast
form of C. albicans cells was populated (Figures 4A–4D).
These experiments provide evidence that both of the
NPF-eCRIB peptides cannot only inhibit the yeast-to-
hyphal transition of C. albicans cells, but can also reverse
hyphal cells into yeast form.
Dose Dependence of Peptide Inhibition on the
Yeast-to-Hyphal Transition of C. albicans
Yeast cells were prepared by the same procedure as that
in the aforementioned experiments and were used to
examine the effect of peptide concentrations on the inhibi-
tion of the yeast-to-hyphal transition of C. albicans cells.
Initially, C. albicans yeast cells were incubated with differ-
ent concentrations of peptides (0–100 mM) for 3 hr at
room temperature, as suggested previously [23], before
culture temperature was increased to 37C. The cell2, November 2007 ª2007 Elsevier Ltd All rights reserved 1277
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Inhibition of Morphologic Transition in CandidaFigure 4. Inhibition of C. albicans Hyphal Growth by NPF-eCRIB Peptides
(A–L) Each peptide was added into fresh hyphal-cell cultures at a final concentration of 100 mM. Different types of cells are shown in the insets.cultures were then shaken for 5 hr at 37C, and an aliquot
of the culture broth was taken out for examination by
optical microscopy. As shown in (A)–(C) for NPF-eCaCla4
and (E)–(G) for NPF-eCst20 in Figure 5, cells can still pro-
liferate into the hyphal form, suggesting that there was no
significant inhibition in the presence of peptides of less
than 25 mM. When the peptide concentration increased
to 25 mM, C. albicans cells were observed to either remain
in the yeast form (NPF-eCaCla4 in Figure 5D) or develop
into the pseudo hyphal form (NPF-eCst20 in Figure 5H).
When peptide concentration further increased to more
than 25 mM, more yeast cells were populated in the media
(Figures 5I and 5J and Figures 5M and 5N for NPF-
eCaCla4 and NPF-eCst20, respectively). After cells were
cultured for 16 hr, the inhibition of peptides during the
yeast-to-hyphal transition became more significant, even
in the presence of a low concentration of peptides (see
Figure 6). In cell cultures in which the initial peptide con-
centration was as low as 12 mM, themajority ofC. albicans
cells were observed to remain in yeast form (Figure 6C for
NPF-eCaCla4 and Figure 6G for NPF-eCst20). In control
experiments, no apparent inhibition was observed for
cultures in the presence of 100 mM CRIB peptide (Figures
5K, 5N, 6K, and 6N). The similar phenomenon was also
observed for cultures in the presence of 100 mMNPF pep-
tide (Figures 5O and 6O). Quantitative analysis showed
that the population of yeast cells increased as a function
of peptide concentration (Figures 5P and 6P).
However, when the peptide concentration was 50 mMor
higher, two NPF-eCRIB peptides exhibited different
effects on cell growth. The NPF-eCaCla4 peptide caused1278 Chemistry & Biology 14, 1273–1282, November 2007 ª20cell lysis (Figures 5I, 5J, 6I, and 6J). In contrast, no cell lysis
was observed in cultures in the presence of the NPF-
eCst20 peptide (with a peptide concentration of up to
100 mM) (Figures 5G, 5M, 6G, and 6M) or in control exper-
iments ([K] for eCaCla4, [N] for eCst20, and [O] for NPF in
Figures 5 and 6). Cell lysis had been assayed with RT-PCR
to confirm that cell fragments were generated from
C. albicans cells (see Figure S4), although it is not clear
whether they are from yeast cells or hyphal cells. It seems
that the cell fragmentation is related to some unknown
mechanism by which the NPF-eCaCla4 peptide can inter-
fere with hyphal growth. Given the complexity of Cdc42-
linked signal transduction, the significant inhibition with
a low-micromolar concentration of peptides (e.g., 12 mM)
suggests that the NPF-eCRIB peptides are promising
potent antifungal agents. Moreover, similar inhibitions
were also observed in other culture media including YPD
and YNB media (data are not shown). Thus, the inhibition
ofC. albicans hyphal growth by both NPF-eCRIB peptides
is a time- and dose-dependent process but is medium
independent.
DISCUSSION
Peptide-mediated protein transduction into mammalian
cells is becoming a widely accepted tool that comple-
ments genetic methods for the study of gene and protein
functions [25–27]. Cargo delivery into microbial cells is
a relatively new area of research, and differential delivery
into pathogenic microbes can be of enormous value for
the development of more effective antimicrobial agents.07 Elsevier Ltd All rights reserved
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Inhibition of Morphologic Transition in CandidaFigure 5. Concentration Dependence of Peptide Inhibition on the C. albicans Yeast-to-Hyphal Transition
(A–P) An 8 hr yeast-cell culture at 25Cwaswashed three times with 13 PBS buffer before the peptide was added, and the reaction was incubated for
3 hr at room temperature. Then fresh Lee’s medium was added, and the reaction was shaken at 37C for 5 hr. The starting concentration of cells was
0.01 OD540, except for in the control experiments with eCRIB peptides ([k] and [m]) or NPF peptide ([o]). Different types of cells are shown in the insets.In this work, we used NPF peptide [22], a previously
well-characterized peptide-transduction domain specific
to microbes, to selectively transduce C. albicans eCRIB
domains of Cdc42-binding kinase effectors (i.e., CaCla4
and Cst20) into C. albicans hyphal cells. Our results re-
vealed that these eCRIB peptides could specifically inhibit
C. albicans hyphal growth in vivo only when they were
transduced into the cells by using the NPF peptide, imply-
ing that NPF-mediated transduction of CRIB peptides (i.e.,
NPF-eCRIBs) can be potent antifungal agents against
candidiasis (i.e., yeast infection).
Interestingly, under the current experimental condi-
tions, no inhibition of C. albicans yeast growth was
observed for the two NPF-eCRIB peptides. Our results
show that NPF peptides do not target C. albicans yeast
cells but do target hyphal cells (Figure 2). A possible expla-
nation is that hyphal cells may have a higher population of
NPF receptors on their surfaces compared to yeast cells,
which needs to be clarified with a biochemical assay in
the future. Nevertheless, the current work suggests that
the signal transduction through the CaCdc42/CaCla4 or
Cst20 interaction can be a key checkpoint for the yeast-
to-hyphal transition or for hyphal growth of C. albicans
cells, implying that the inhibition of these protein-proteinChemistry & Biology 14, 1273–1282interactions by the eCRIB peptides may not affect the
interaction of CaCdc42 with other signaling proteins. Pre-
viously, genetic studies showed that the deletion of both
Cdc42 alleles could completely abort Candida cell growth
[17]. Therefore, the current results raise new questions
regarding whether or how CaCdc42 regulates the growth
of yeast and hyphal cells differentially in C. albicans. By
comparison, the functional aspects of Cdc42 regulating
cell polarity have been extensively explored [28]. To an-
swer this question, further genetic and biochemical inves-
tigations are needed. Two previous genetic models of
C. albicans, which overexpress Cdc42 and is haploinsuffi-
cient for Cdc42 [17], would be useful for dissecting
Cdc42-linked signal transduction pathways, in combina-
tion with our chimeric inhibitor peptides.
The modulation of protein-protein interactions has pro-
vided the molecular basis for our understanding of many
biological and cell signaling pathways [29]. Manipulation
of protein-protein interactions by rewiring signal pathways
[30, 31] has not only opened up a new area for synthetic bi-
ology in studying the functional complexity of cells [32, 33],
but it has also brought a novel concept of signaling trans-
duction therapy into the front line of modern drug research
[34]. These investigations can enhance our understanding, November 2007 ª2007 Elsevier Ltd All rights reserved 1279
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Inhibition of Morphologic Transition in CandidaFigure 6. Concentration Dependence of Peptide Inhibition on the C. albicans Yeast-to-Hyphal Transition
(A–P) The conditions were the same as those in Figure 5, except that samples were taken from the culture after 16 hr.of themolecularmechanismsof humandiseases, because
most of these diseases are related to dysregulation of
intra- and intercellular signaling communication pathways.
The current work provides an important and timely exam-
ple of the concept by preventing pathogenic cell growth
through selectively interrupting protein-protein interac-
tions relevant to signal transductions.
SIGNIFICANCE
Protein-protein interactions regulating biological and
cell signaling are the coming wave of drug target
discovery in the postgenomics era because many
diseases, such as cancers and diabetes, are related
to aberrant signal transduction. Disruption of these
protein-protein interactions is still a major challenge
for the discovery of small-molecule drugs (SMDs)
due to the existence of a large interface in these inter-
actions. On the contrary, peptides or peptidomimetics
have unique advantages over SMDs in inhibiting pro-
tein-protein interactions with respect to the increased
time efficiency of discovery efforts. C. albicans is an
opportunistic fungal pathogen, and its morphologic
transition from yeast to hyphae is pathogenesis rele-
vant. The transition is regulated by multiple cellular1280 Chemistry & Biology 14, 1273–1282, November 2007 ª200signaling transduction pathways, one of which in-
volves C. albicans Cdc42 (CaCdc42), a small GTPase,
interacting specifically with the extended CRIB
(eCRIB) domains of Cdc42-binding effectors. In the
current study, these eCRIB peptides were utilized to
inhibit the morphologic transition through disrupting
protein-protein interactions engaged by CaCdc42.
Our results demonstrate that specific inhibition of
the interactions of CaCdc42 with its downstream ef-
fectors by internalized eCRIB peptides can inactivate
and even reverse the pathogenically related morpho-
logic transition of C. albicans. Therefore, the current
work provides a glimpse into a promising new gener-
ation of anticandidiasis agents, because C. albicans
cells would be arrested in nonpathogenic yeast forms
and eventually be killed by host factors such as mac-
rophages. Most significantly, the work brings the con-
cept of manipulating signaling transduction pathways
into the front line of drug design for other signal
transduction-related diseases. Aswell, these peptides
are excellent templates that can be utilized for the
rational design of peptidomimetics or SMDs. Conse-
quently, the strategy described in this work may ren-
der it applicable to a broad range of human diseases
caused by aberrant protein-protein interactions.7 Elsevier Ltd All rights reserved
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Cultures of C. albicans Cells
The C. albicans SC5314 strain was maintained by periodic transfer to
slants of YPD medium (1% yeast extract, 2% peptone, 2% dextrose).
Overnight cultures were inoculated from a fresh colony and were
grown in YPD (pH 6.0–6.5) at 30C. The overnight cultures were diluted
to an OD540 of 0.05–0.1 in YPD or YPD plus 10% fetal bovine serum
(FBS) from Invitrogen (Carlsbad, CA) and were grown at 30C for yeast
and 37C for hyphal cells. Cultures grown in Lee’s medium containing
10% glucose were started from an overnight culture in 1 l temperature-
adjusted medium and grew at either 37C to induce hyphae or at 25C
to maintain yeast growth.
Peptide Preparation
All of the peptides, including NPF, CRIB domains (eCaCla4 and
eCst20), and NPF-conjugated CRIB domains (NPF-eCaCla4 and
NPF-eCst20), used in the current study were prepared by using a
recombinant peptide expression system as described previously
[35]. A detailed procedure is described in the Supplemental Data.
The identity of the final products was verified by electrospray mass
spectrometry.
Preparation of Cdc42 Proteins
The expression plasmid for Candida Cdc42 (CaCdc42) was described
previously [20]. A similar protocol was used to construct expression
vector for human Cdc42 (HsCdc42). Briefly, DNA fragments encoding
human Cdc42 protein (residues 1–178) were amplified from a GST
fusion protein expression plasmid [36] by a standard PCR method by
using pfu polymerase. Through PCR, two restriction sites, Nde I and
BamH I, were generated at the 50 end and 30 end, respectively. A
stop codon, TAG, was placed immediately after the codon for residue
178. The PCR fragment was subcloned into pET-15b vector (Novagen,
Madison, WI), and the resulting construct was defined as pHsCdc42.
Both CaCdc42 and HsCdc42 proteins were expressed in the E. coli
BL21 strain as hexahistidine fusion proteins. The proteins were purified
and nucleotide exchanged as described previously [20].
Preparation of GFP Fusion Protein
The NPFSD-GFP expression plasmid (the gift of Dr. Liam Good, Karo-
linska Institute) [23] was used as a template to construct expression
vectors for NPF-CRIB-GFP fusion proteins. To facilitate protein purifi-
cation, a hexahistidine tag was inserted between the peptide and GFP
(see Figure 2B). The fusion proteins were purified by Ni-NTA agarose
affinity chromatography with a native condition purification procedure,
provided by the supplier (QIAGEN, Mississauga, ON). The proteins
were eluted with a buffer containing 200 mM imidazole and were
dialyzed against 50 mMphosphate buffer (pH 6.5) overnight to remove
imidazole.
Peptide-Binding Assay
Peptide binding affinity was measured for the interaction of the pep-
tides with sNBD-labeled CaCdc42 or HsCdc42, and extrinsic fluores-
cence enhancements were measured with a Hitachi F-2500 fluores-
cence spectrophotometer as essentially described in previous
publications [20]. The KD values for the binding were determined by fit-
ting the fluorescence titration data to a simple bimolecular association
model as described by Leonard et al. [37]. The fluorescence intensity
(F) is related to the dissociation constant (KD), the protein concentra-
tion (P), and the peptide concentration (L) as follows
F =F0 + ðFt  F0Þ
2
4ðKd +LT +PT Þ 
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ðKd + LT +PT Þ24PTLT
q
2PT
3
5; (1)
where F0 and Ft are the fluorescence intensities at the starting and end
points of the titration, respectively. PT is the total concentration of
sNBD-labeled Cdc42, and LT is the total concentration of the peptide
at any point in the titration. Fitting of the data was carried out byChemistry & Biology 14, 1273–1282using the computer program Microcal Origin 6.0 (Northampton, MA).
Average KD values were determined from five independent measure-
ments.
Mammalian Cell Culture
HeLa cells were maintained in Minimum Essential Medium with Earle’s
Salt (E-MEM) supplemented with 2 nM L-glutamine, 10% (vol/vol) fetal
bovine serum (GIBCO-BRL), 1% (vol/vol) penicillin-streptomycin
(GIBCO-BRL), and 0.2% (vol/vol) fungizone amphotericin B (GIBCO-
BRL). The cells were cultured in a humidified incubator at 37C and
in the presence of 5% CO2.
When themammalian cells were more than 80%confluent,5–20 ml
GFP fusion proteins was added to the medium. Cells adhered on the
plate were washed three times with PBS and were visualized by using
the phase-contrast function on a Nikon PCM2000 confocal micro-
scope at 0, 3, 5, and 8 hr after posttransduction.
Peptide Inhibition of C. albicans Cells
An overnight cell culture at 25C in Lee’smediumwas used to generate
yeast cells, and an overnight cell culture in Lee’s medium at 37C was
used to generate hyphal cells. The overnight cell culture was used to
inoculate fresh Lee’s medium, and the starting concentration of cells
was an OD540 of 0.01. Each peptide was added into cell cultures
with a final concentration between 0 and 100 mM. A total of 3.5 ml
culture liquid was taken for light microscopic observation of cell
morphogenesis.
NMR Measurements
NMR spectra were acquired with a Bruker 600 MHz NMR spectrome-
ter at 25C by using standard pulse sequences [38]. The NMR samples
were prepared by dissolving the peptides in 50 mM phosphate buffer
(pH 6.5). Spectral processing, display, and analysis were performed by
using the XwinNMR software package (Version 3) supplied with the
spectrometer system.
Supplemental Data
Supplemental Data include information regarding in vitro peptide
inhibition of kinase activation and the cell lysis assy and are available
at http://www.chembiol.com/cgi/content/full/14/11/1273/DC1/.
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